Knight Therapeutics has entered into an exclusive license agreement with Amneal Pharmaceuticals giving it rights to apply for regulatory approval of IPX203 in Canada and across Latin America, and, if granted, to market the Parkinson’s disease treatment there. IPX203 is an investigational, extended-release oral formulation…
News
The Michael J. Fox Foundation for Parkinson’s Research (MJFF) has awarded an $873,000 grant to Vesper Bio to advance the preclinical development of small-molecule therapies aiming to increase progranulin levels in people with Parkinson’s disease. Low levels of progranulin, a protein critical for immune activity and…
Being a caregiver for someone with Parkinson’s disease can be difficult, but for family members, providing care is not a burden, it’s a partnership, an opportunity to express their love. That’s according to interviews with 16 current and former Parkinson’s care partners. The findings were published in the…
A four-week exercise program to improve balance, directed by a smartphone app, can help older adults walk at a faster pace and correct their posture, a study has found, features that may help to prevent falls, a common complication of Parkinson’s disease. The app, being developed by scientists at…
A new study by scientists in Australia may be set to overturn more than a decade of thinking that the use of the KTP molecule could work as a treatment for Parkinson’s disease. Titled “Interaction of PINK1 with nucleotides and kinetin” and published in Scientific Advances,…
Led by the Michael J. Fox Foundation for Parkinson’s Research (MJFF), an international group of patients, researchers, and industry leaders has proposed a framework for defining and staging Parkinson’s disease based on its underlying biology rather than by hallmark disease symptoms. Called the neuronal alpha-synuclein disease integrated…
Scientists have proposed a new way to classify Parkinson’s disease based on biological changes associated with the disorder. “Without looking at the biology, you can’t get answers. And without answers, we won’t have much-needed breakthroughs in Parkinson’s,” Anthony Lang, MD, a researcher at the Krembil Brain Institute in Canada,…
Centogene and The Michael J. Fox Foundation (MJFF) are teaming up on a research project to investigate genetic risk factors for Parkinson’s disease, with a particular focus on GBA gene mutations. This project’s main goal is to better understand how certain variations in the GBA gene are connected…
Before deep brain stimulation (DBS), a surgical treatment for Parkinson’s disease, made it possible for guitarist Fabio Dwyer to again play and return to his livelihood in Canada, all had seemed lost. Be it performing, composing, or teaching, Dwyer’s world was ensconced in music. He had helped…
ProMIS Neurosciences announced arriving at a lead candidate vaccine against the misfolded alpha-synuclein protein, which the company plans to develop as a treatment for Parkinson’s disease and related disorders. The potential vaccine, known as PMN400, is moving into preclinical testing in animal models of Parkinson’s. “We are…
Recent Posts
- New $2M MJFF grant backs Parkinson’s walking study at Boston University
- My fear of falling has gotten worse since my Parkinson’s diagnosis
- New compound targets mitochondrial damage in Parkinson’s models
- Environmental factors may impact Parkinson’s disease risk: Dutch study
- Finding solutions for REM sleep behavior disorder with Parkinson’s